FLT-PET for differentiating between uterine leiomyosarcoma and leiomyoma: A prospective study

FLT-PET for differentiating between uterine leiomyosarcoma and leiomyoma: A prospective study - FLT-PET for differentiating between uterine leiomyosarcoma and leiomyoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003338

Enrollment

Registered

2010-03-15

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine smooth muscle tumor

Interventions

FLT-PET, FDG-PET and MRI

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Presence of uterine smooth muscle tumor confirmed by US, CT or MRI 2) Potentiality of uterine leiomyosarcoma 3) Without an experience of treatment for the tumor except for hormone therapy 4) Final diagnosis at 6 month after scan can be confirmed by the referring physician

Exclusion criteria

Exclusion criteria: 1) Poor general condition 2) Poor control of diabetes mellitus 3) Pregnant or the possibility of pregnancy 4) Contraindication to MRI 5) Regarded ad unsuitable by responsible investigator

Design outcomes

Primary

Measure	Time frame
Diagnostic ability of FLT-PET for differentiating between uterine leiomyosarcoma and leiomyoma	—

Countries

Japan

Contacts

Public ContactTomohiko Yamane

Institute of Biomedical Research and Innovation Division of Molecular Imaging

yamane@fbri.org078-304-5200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026